Amylyx Pharmaceuticals Inc

For the period ended Jun 30, 2024. Filed Aug 8, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 8, 2024

AMLX$30.91+2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Product revenue, net	$(1,023)	$98,216	$87,620	$169,644
Operating expenses:
Cost of sales	8	5,580	5,953	10,863
Cost of sales - inventory impairment and loss on firm purchase commitments	7,410	—	117,871	—
Research and development	23,347	29,044	59,955	53,236
Selling, general and administrative	21,647	43,391	79,406	87,397
Restructuring expenses	22,851	—	22,851	—
Total operating expenses	75,263	78,015	286,036	151,496
(Loss) income from operations	(76,286)	20,201	(198,416)	18,148
Other income, net:
Interest income	4,069	3,887	8,395	7,605
Other expense, net	(483)	(81)	(1,230)	(343)
Total other income, net	3,586	3,806	7,165	7,262
(Loss) income before income taxes	(72,700)	24,007	(191,251)	25,410
Provision for income taxes	—	1,933	242	1,763
Net (loss) income	$(72,700)	$22,074	$(191,493)	$23,647
Net (loss) income per share
Basic	$(1.07)	$0.33	$(2.82)	$0.35
Diluted	$(1.07)	$0.31	$(2.82)	$0.34
Weighted-average shares used in computing net (loss) income per share
Basic	68,024,929	67,233,617	67,939,642	66,976,871
Diluted	68,024,929	70,132,040	67,939,642	70,471,821

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.